Manufacturers report positive results for dupilumab in childhood asthma

In the VOYAGE trial (n=408), dupilumab was found to reduce the date of severe asthma attacks vs placebo in children with asthma aged 6 to 11 years by between 65% and 59% over one year.

PharmaTimes